About this event

  • Date and time Fri 14 Feb 2020 from 8:45am to 4:55pm
  • Location Royal Society of Medicine
  • Organised by Radiology

This highly commended one-day teaching course focuses on the value and uses of MR and PET/CT imaging in the entire patient journeys from suspected prostate cancer to the advanced disease state using the framework of definable clinical states.

World-renowned speakers will cover every aspect of the radiology path throughout the diagnosis and treatment of prostate cancer, with a focus on how imaging advances clinical care. The idea is to lay out how next generation imaging technologies contribute to the personalization of care.

Learning objectives:

  • To know in detail the pathologic states, problems of categorisation and clinical needs of patients in each clinical state.
  • To understand how imaging can help meet clinical priorities and so promote the personalisation of care in advancing clinical states.
  • To show how next generation prostate imaging (multiparametric MRI & MR-directed biopsies) and whole-body assessments (whole body MRI & PET/CT) with clinical biomarkers, create opportunities to support and manage pathways of patients.

Tickets

Early bird pricing available until 15 November 2019.

Member

RSM Fellow RSM Associate RSM Retired Fellow RSM Trainee RSM Student
£95.00 £55.00 £55.00 £55.00 £30.00

Non - Member

Consultant / GP Non Healthcare Professional AHP / Nurse / Midwife Trainee Student
£150.00 £95.00 £75.00 £75.00 £45.00

Key speakers

Prof Anwar Padhani

Professor Anwar Padhani

Consultant, Radiologist, Paul Strickland Scanner Centre, Mount Vernon Cancer Centre.

Speaker's biography

Prof. Anwar R. Padhani is an internationally recognized Oncological MRI radiologist at Paul Strickland Scanner Centre, Mount Vernon Cancer Centre, London. He is Professor of Cancer Imaging at the Institute of Cancer Research, London. He is the executive chairperson of the International Cancer Imaging Society (ICIS). He is a recognised cancer imaging expert in prostate cancer imaging. He has been instrumental in introducing multiparametric prostate MRI into clinical practice contributing to international guidelines development including the ESUR/ACR prostate PI-RADS system, the St Gallen advanced prostate cancer consensus conference (APCCC) committee and the American Society of Clinical Oncology (ASCO) advanced prostate cancer guidelines. He led the metastasis response assessment system (MET-RADS) committee on the use of whole body MRI for advanced prostate cancer. Prof. Padhani has published numerous textbook chapters, educational and scientific journal reviews and published more than 100 full scientific articles in peer reviewed journals. There have been over 12,000 publications reads and citations of his works. To his credit, he has been awarded outstanding/honoured teacher awards from the ISMRM and the RSNA. He is the recipient of the ICIS 2017 Gold medal.

prof Heather Payne

Professor Heather Payne

Consultant, Oncologist, University College London Hospitals, London. Chair of the British Uro-oncology Group (BUG), and serves on the Prostate Cancer Charter for Action and the Department of Health Prostate Cancer Advisory Group.

Speaker's biography

Professor Payne was appointed as a Consultant in Clinical Oncology at University College Hospital, London in 1997. She trained at St Marys Hospital London  Medical School and after qualifying spent some working in general medicine both in London and also in Haiti. She returned to London to train as a clinical oncologist and during this time developed an interest in urological oncology. She has a busy practice specialising in the management of urological malignancies in London where she works within a multidisciplinary team. She is actively involved in clinical research in all these therapeutic areas and has pioneered a programme of high dose-rate brachytherapy for prostate cancer at the UCH site.

Professor Payne's current research interests also include hormone therapy as adjuvant treatment for locally advanced disease, sensitisation of hormones and radiotherapy, maximal androgen blockade, predictive indices for bowel toxicity with radiotherapy, chemotherapy and quality of life and decision-making for men with prostate cancer. She is principal investigator in a number of international multi-centre and local studies. She is a trustee of the Prostate Cancer Research Centre and the chairman of the British Uro-oncology Group (BUG). She also serves on CTAAC, the Prostate Cancer Charter for Action, and the Department of Health Prostate Cancer Advisory Group for the United Kingdom.

Dr Giuseppe Petralia

Dr Giuseppe Petralia

ConsultantRadiologistEuropean Institute of OncologyMilan, Italy

Speaker's biography

Giuseppe Petralia has specialized in Radiodiagnostics with a thesis on imaging of angiogenesis in tumours, after a period of research at Massachusetts General Hospital in Boston (USA).

Since 2005 he has been working at the European Institute of Oncology (IEO) in Milan, where he introduced the Whole-Body Diffusion in 2009.

Today he is a researcher at the University of Milan and responsible for IEO Magnetic Resonance.

He is a Fellow of the International Cancer Imaging Society (ICIS) and advisor of the RM section of the Italian Society of Medical Radiology (SIRM).

He is the author of about 60 articles in scientific journals and speaker at numerous international congresses, in many of which he holds training courses on the most innovative applications of MRI in cancer patients.

Professor Gary Cook

Consultant, Nuclear Medicine Physician, King’s College London, Division of Imaging Sciences and Biomedical EngineeringGuy's & St Thomas' Hospitals NHS Foundation Trust. Chair of Clinical PET Imaging in Imaging Sciences and Cancer Imaging Department at Kings College and Guy’s & St Thomas PET Centre. He specializes in PET imaging in oncology, multiparametric, multimodality imaging including PET/MRI. 

Speaker's biography

Gary Cook trained in radiology and nuclear medicine in London, completing his MD in Quantitative 18F-fluoride PET in Metabolic Bone Diseases at King’s College London. He was appointed to the Chair of Clinical PET Imaging in the School of Biomedical Engineering and Imaging Sciences Cancer Imaging Department and KCL and Guy’s & St Thomas PET Centre and as an honorary consultant physician at Guy’s and St Thomas’ Hospitals in 2011.

Research interests include evaluation of novel SPECT and PET tracers in oncology, multiparametric, multimodality imaging biomarker development and measurement of tumour heterogeneity, multimodality imaging of skeletal metastases and development of oncologic hybrid imaging, including PET/MRI. He is joint clinical lead for the clinical PET service and module lead and examiner for the KCL Nuclear Medicine MSc.

Agenda

View the programme

Registration, tea and coffee
Welcome and introduction

Prostate cancer diagnosis and staging

Prostate cancer diagnosis and staging

Chair: Professor Anwar PadhaniConsultant, Radiologist, Paul Strickland Scanner Centre, Mount Vernon Cancer Centre

Detection with magnetic resonance imaging including scoring systems

Dr Heminder Kaur SokhiConsultant Radiologist, Department of Radiology, The Hillingdon Hospitals NHS Foundation Trust, Department of Radiology, Paul Strickland Scanner Centre, Mount Vernon Hospital

Magnetic resonance imaging directed biopsy strategies

Professor Hashim AhmedConsultantUrologistDepartment of Surgery and CancerImperial College London

Tea and coffee break
Impacts of magnetic resonance imaging directed pathway

Professor Anwar PadhaniConsultant, Radiologist, Paul Strickland Scanner Centre, Mount Vernon Cancer Centre  

Risk-based staging of known cancers and therapy decision making

Dr Giuseppe PetraliaConsultantRadiologistEuropean Institute of OncologyMilan, Italy

Panel discussion
Lunch

Advancing disease

Advancing disease states

Chair: Professor Anwar PadhaniConsultant, Radiologist, Paul Strickland Scanner Centre

Biochemical recurrence imaging detection

Professor Gary CookConsultant, Nuclear Medicine Physician, King’s College London, Division of Imaging Sciences and Biomedical Engineering, Guy's and St Thomas' NHS Foundation Trust

Imaging directed salvage treatment

Dr Alison Tree, Consultant Radiologist, Radiotherpy, The Royal Marsden NHS Foundation Trust

Tea and coffee break
Advanced prostate cancer – therapy choices

Professor Heather Payne, Consultant, Oncologist, University College London Hospitals NHS Foundation Trust

Advanced prostate cancer – imaging therapy monitoring

Dr Nina Tunariu, Consultant, Radiologist, The Royal Marsden NHS Foundation Trust

Panel discussion
Concluding remarks
Close of meeting

Location

Royal Society of Medicine, 1 Wimpole St, Marylebone, London, London, W1G 0AE, United Kingdom